Does the MOSES study provide sufficient evidence for Eprosartan against Nitrendipine? [2]

Stroke

Volumn 37, Issue 6, 2006, Pages 1357-

  Larsen, Klaus ^a   Hornnes, Nete ^a   Boysen, Gudrun ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPROSARTAN; NITRENDIPINE; ACRYLIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; IMIDAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; FOLLOW UP; HUMAN; LETTER; MORBIDITY; MORTALITY; POISSON DISTRIBUTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; NOTE; RANDOMIZED CONTROLLED TRIAL;

ACRYLATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR ACCIDENT; HUMANS; IMIDAZOLES; NITRENDIPINE; RANDOMIZED CONTROLLED TRIALS; THIOPHENES;

EID: 33745163573     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000222992.66497.54     Document Type: Letter

References (4)

1. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Morbidity and mortality after stroke, Eprosartan compared with Nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1224.
2. McCullagh P, Nelder JA. Generalized Linear Models. London: Chapman & Hall; 1989.
3. Dean C, Lawless JF. Tests for detecting overdispersion in Poisson regression models. J Am Stat Assoc. 1989;84:467-472.
4. Cameron AC, Trivedi PK. Econometric models based on count data: comparisons and applications of some estimators and tests. Journal of Applied Econometrics. 1986;1:29-53.